Zheng M, Lu N, Ren M, et al. - Researchers investigated the link between visfatin (an adipokine) and major adverse cardiovascular events (MACEs) among patients suffering from acute myocardial infarction (AMI). A sum of 238 patients (183 AMI and 55 control) who had coronary angiography were enrolled. An average follow-up of 19.3 months was performed in AMI patients and the final analysis was done including 159 patients. Higher serum visfatin levels were detected in patients with AMI vs controls. The total incidence of MACEs was estimated to be 11.32% (18/159) in AMI patients. For the prediction of MACEs, 8.799 ng/mL was identified as the best cut-off value of visfatin on the curve of receiver-operating characteristic, after computing the Youden index. Overall, AMI patients had increased serum visfatin levels which were shown to be correlated with an earlier onset as well as a higher incidence of MACEs.